Skip to main content
Top

09-05-2024 | Vomiting | Special Article

Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023

Authors: Masamitsu Kobayashi, Jun Kako, Arisa Iba, Ayako Okuyama, Keiko Ozawa, Masakazu Abe, Makoto Wada, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Yong-Il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Takako Eguchi Nakajima, Naoki Nakamura, Junichi Nishimura, Mayumi Noda, Kazumi Hayashi, Takahiro Higashi, Narikazu Boku, Koji Matsumoto, Yoko Matsumoto, Kenji Okita, Nobuyuki Yamamoto, Kenjiro Aogi, Keiko Iino

Published in: International Journal of Clinical Oncology

Login to get access

Abstract

Background

Anticipatory chemotherapy-induced nausea and vomiting (CINV) is a conditioned response influenced by the severity and duration of previous emetic responses to chemotherapy. We aimed to evaluate the efficacy of non-pharmacologic interventions for anticipatory CINV among patients with cancer.

Methods

We conducted a systematic search in databases, including PubMed, the Cochrane Library, CINAHL, and Ichushi-Web, from January 1, 1990, to December 31, 2020. Randomized controlled trials, non-randomized designs, observational studies, or case–control studies that utilized non-pharmacological therapies were included. The primary outcomes were anticipatory CINV, with an additional investigation into adverse events and the costs of therapies. The risk-of-bias for each study was assessed using the Cochrane risk-of-bias tool, and meta-analysis was performed using Revman 5.4 software.

Results

Of the 107 studies identified, six met the inclusion criteria. Three types of non-pharmacological treatments were identified: systematic desensitization (n = 2), hypnotherapy (n = 2), and yoga therapy (n = 2). Among them, systematic desensitization significantly improved anticipatory CINV as compared to that in the control group (nausea: risk ratio [RR] = 0.60, 95% confidence interval [CI] = 0.49–0.72, p < 0.00001; vomiting: RR = 0.54, 95% CI = 0.32–0.91, p = 0.02). However, heterogeneity in outcome measures precluded meta-analysis for hypnotherapy and yoga. Additionally, most selected studies had a high or unclear risk of bias, and adverse events were not consistently reported.

Conclusions

Our findings suggest that systematic desensitization may effectively reduce anticipatory CINV. However, further research is warranted before implementation in clinical settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lorusso D, Bria E, Costantini A et al (2017) Patients' perception of chemotherapy side effects: Expectations, doctor−patient communication and impact on quality of life - An Italian survey. Eur J Cancer Care (Engl) 26(2):e12618CrossRef Lorusso D, Bria E, Costantini A et al (2017) Patients' perception of chemotherapy side effects: Expectations, doctor−patient communication and impact on quality of life - An Italian survey. Eur J Cancer Care (Engl) 26(2):e12618CrossRef
2.
go back to reference Chow R, Yin LB, Baqri W et al (2023) Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis. Support Care Cancer 31:505CrossRefPubMed Chow R, Yin LB, Baqri W et al (2023) Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis. Support Care Cancer 31:505CrossRefPubMed
4.
go back to reference Andrykowski MA, Jacobsen PB, Marks E et al (1988) Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer 62:2607–2613CrossRefPubMed Andrykowski MA, Jacobsen PB, Marks E et al (1988) Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer 62:2607–2613CrossRefPubMed
5.
go back to reference Alba E, Bastus R, de Andres L et al (1989) Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology 46:26–30CrossRefPubMed Alba E, Bastus R, de Andres L et al (1989) Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology 46:26–30CrossRefPubMed
6.
go back to reference Morrow GR, Rosenthal SN (1996) Models, mechanisms and management of anticipatory nausea and emesis. Oncology 53(Suppl 1):4–7CrossRefPubMed Morrow GR, Rosenthal SN (1996) Models, mechanisms and management of anticipatory nausea and emesis. Oncology 53(Suppl 1):4–7CrossRefPubMed
7.
go back to reference Kamen C, Tejani MA, Chandwani K et al (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 722:172–179CrossRefPubMed Kamen C, Tejani MA, Chandwani K et al (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 722:172–179CrossRefPubMed
8.
go back to reference Hursti T, Fredikson M, Börjeson S et al (1992) Association between personality characteristics and the prevalence and extinction of conditioned nausea after chemotherapy. J Psychosoc Oncol 10:59–77CrossRef Hursti T, Fredikson M, Börjeson S et al (1992) Association between personality characteristics and the prevalence and extinction of conditioned nausea after chemotherapy. J Psychosoc Oncol 10:59–77CrossRef
9.
go back to reference Sticht MA, Rock EM, Limebeer CL et al (2015) Endocannabinoid mechanisms influencing nausea. Int Rev Neurobiol 125:127–162CrossRefPubMed Sticht MA, Rock EM, Limebeer CL et al (2015) Endocannabinoid mechanisms influencing nausea. Int Rev Neurobiol 125:127–162CrossRefPubMed
10.
go back to reference Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356–1367CrossRefPubMed Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356–1367CrossRefPubMed
11.
go back to reference Hesketh PJ, Bohlke K, Lyman GH et al (2016) Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol 34:381–386CrossRefPubMed Hesketh PJ, Bohlke K, Lyman GH et al (2016) Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol 34:381–386CrossRefPubMed
12.
go back to reference Malik IA, Khan WA, Qazilbash M et al (1995) Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18:170–175CrossRefPubMed Malik IA, Khan WA, Qazilbash M et al (1995) Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18:170–175CrossRefPubMed
13.
go back to reference Razavi D, Delvaux N, Farvacques C et al (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11:1384–1390CrossRefPubMed Razavi D, Delvaux N, Farvacques C et al (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11:1384–1390CrossRefPubMed
15.
go back to reference Aapro M, Scotté F, Escobar Y et al (2021) Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. Oncologist 26:e1073–e1082CrossRefPubMedPubMedCentral Aapro M, Scotté F, Escobar Y et al (2021) Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. Oncologist 26:e1073–e1082CrossRefPubMedPubMedCentral
16.
go back to reference Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38:2782–2797CrossRefPubMed Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38:2782–2797CrossRefPubMed
19.
go back to reference Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg 88:105906CrossRefPubMed Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg 88:105906CrossRefPubMed
20.
go back to reference Minds Manual Developing Committee ed. (2016) Minds Manual for Guideline Development 2017. Tokyo: Japan Council for Quality Health Care. Minds Manual Developing Committee ed. (2016) Minds Manual for Guideline Development 2017. Tokyo: Japan Council for Quality Health Care.
21.
go back to reference Hamdani D, Prasetyo A, Anggorowati A (2020) The effect of hypnotherapy on anticipatory nausea in head and neck cancer patients undergoing chemotherapy. Nurse Media J Nurs 10:317–328CrossRef Hamdani D, Prasetyo A, Anggorowati A (2020) The effect of hypnotherapy on anticipatory nausea in head and neck cancer patients undergoing chemotherapy. Nurse Media J Nurs 10:317–328CrossRef
22.
go back to reference Anestin AS, Dupuis G, Lanctôt D et al (2017) The effects of the Bali Yoga Program for breast cancer patients on chemotherapy-induced nausea and vomiting: Results of a partially randomized and blinded controlled trial. J Evid Based Complementary Altern Med 22:721–730CrossRefPubMedPubMedCentral Anestin AS, Dupuis G, Lanctôt D et al (2017) The effects of the Bali Yoga Program for breast cancer patients on chemotherapy-induced nausea and vomiting: Results of a partially randomized and blinded controlled trial. J Evid Based Complementary Altern Med 22:721–730CrossRefPubMedPubMedCentral
23.
go back to reference Raghavendra RM, Nagarathna R, Nagendra HR et al (2007) Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients. Eur J Cancer Care (Engl) 16:462–474CrossRefPubMed Raghavendra RM, Nagarathna R, Nagendra HR et al (2007) Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients. Eur J Cancer Care (Engl) 16:462–474CrossRefPubMed
24.
go back to reference Marchioro G, Azzarello G, Viviani F et al (2000) Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. Oncology 59:100–104CrossRefPubMed Marchioro G, Azzarello G, Viviani F et al (2000) Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. Oncology 59:100–104CrossRefPubMed
25.
go back to reference Morrow GR, Asbury R, Hammon S et al (1992) Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists. Health Psychol 11:250–256CrossRefPubMed Morrow GR, Asbury R, Hammon S et al (1992) Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists. Health Psychol 11:250–256CrossRefPubMed
26.
go back to reference Morrow GR, Morrell C (1982) Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307:1476–1480CrossRefPubMed Morrow GR, Morrell C (1982) Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307:1476–1480CrossRefPubMed
27.
go back to reference Coates A, Abraham S, Kaye SB et al (1983) On the receiving end–patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMed Coates A, Abraham S, Kaye SB et al (1983) On the receiving end–patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMed
28.
go back to reference Dranitsaris G, Leung P, Warr D (2001) Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 9:611–618CrossRefPubMed Dranitsaris G, Leung P, Warr D (2001) Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 9:611–618CrossRefPubMed
29.
go back to reference Okuyama A, Nakamura F, Higashi T (2014) Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan. Support Care Cancer 22:1789–1795CrossRefPubMed Okuyama A, Nakamura F, Higashi T (2014) Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan. Support Care Cancer 22:1789–1795CrossRefPubMed
30.
go back to reference Tamura K, Aiba K, Saeki T et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855–865CrossRefPubMed Tamura K, Aiba K, Saeki T et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855–865CrossRefPubMed
31.
go back to reference Koch S, Wein A, Siebler J et al (2013) Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project. Support Care Cancer 21:2395–2402CrossRefPubMed Koch S, Wein A, Siebler J et al (2013) Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project. Support Care Cancer 21:2395–2402CrossRefPubMed
Metadata
Title
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023
Authors
Masamitsu Kobayashi
Jun Kako
Arisa Iba
Ayako Okuyama
Keiko Ozawa
Masakazu Abe
Makoto Wada
Tatsuo Akechi
Hirotoshi Iihara
Chiyo K. Imamura
Yong-Il Kim
Hidenori Sasaki
Eriko Satomi
Masayuki Takeda
Ryuhei Tanaka
Takako Eguchi Nakajima
Naoki Nakamura
Junichi Nishimura
Mayumi Noda
Kazumi Hayashi
Takahiro Higashi
Narikazu Boku
Koji Matsumoto
Yoko Matsumoto
Kenji Okita
Nobuyuki Yamamoto
Kenjiro Aogi
Keiko Iino
Publication date
09-05-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-024-02536-w
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine